su011248

Metastasis

Amsterdam UMC, location VUmcPhase 2/3Dormant

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 48/ 100
Competitive Position: 81/ 100

Competitive context

21 Active assets in the Metastasis cohort.

Asset / Sponsor	Phase	Rating
PAMIDRONIC ACID Ottawa Hospital Research Institute	Phase 4	BB
TAMOXIFEN National Cancer Center, Korea	Phase 3	BB
Palbociclib Eli Lilly and Company	Phase 3	BB
Abiraterone Acetate Merck Sharp & Dohme LLC	Phase 3	BB
Sorafenib Wake Forest University Health Sciences	Phase 4	BB

View all 46 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.